Becton, Dickinson and Company (BDX) exceeded analysts’ expectations for fourth-quarter earnings and sales, driven by robust growth in its Medical segment and a strategic focus on higher-growth areas. The company also announced a dividend increase and provided optimistic guidance for fiscal year 2025, anticipating strong revenue growth fueled by new innovations and acquisitions.